| Mrs Dominique Michelle Well, ARNP | |
|
4715 42nd Ave Sw, Seattle, WA 98116-4507 | |
| (206) 265-3642 | |
| Not Available |
| Full Name | Mrs Dominique Michelle Well |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner - Family |
| Location | 4715 42nd Ave Sw, Seattle, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003116815 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | AP30006054 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Dominique Michelle Well, ARNP 4715 42nd Ave Sw, Seattle, WA 98116-4507 Ph: (206) 265-3642 | Mrs Dominique Michelle Well, ARNP 4715 42nd Ave Sw, Seattle, WA 98116-4507 Ph: (206) 265-3642 |
News Archive
Tufts University researchers have discovered a possible explanation for the occurrence of a genetic error that causes over a dozen neuromuscular and neurodegenerative disorders, including Huntington's disease, myotonic dystrophy and forms of spinocerebellar ataxia.
Young women diagnosed with breast cancer are uniquely impacted by issues often not faced by older women. Breast cancer is often detected at later stages, increasing diagnoses of more advanced cancers. The impact of cancer treatment on fertility, body image, financial challenges, and slightly higher mortality rates are significant concerns for this population.
Stand Up To Cancer, joined by the Lustgarten Foundation for Pancreatic Cancer Research, LUNGevity, and the American Lung Association, announced today four teams of top researchers who will carry out an attack on cancers of the lung and pancreas using a radical new approach of "interception" of cancers at very early stages, when they can be more successfully treated.
Hitachi High-Technologies Corporation and QIAGEN N.V. have entered into a long-term strategic collaboration involving initiatives to deliver important advances in molecular testing.
Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced the initiation of a Phase III clinical trial for TAK-700 in the U.S. in patients with advanced prostate cancer. TAK-700 is a selective, oral, non-steroidal androgen synthesis inhibitor that in preclinical studies has been shown to selectively bind to and inhibit the enzyme 17,20 lyase in both the testes and adrenal glands.
› Verified 5 days ago
Mrs. Joanne Lynn Osetsky, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 550 17th Ave, Ste 110, Seattle, WA 98122 Phone: 206-320-3470 Fax: 206-320-3471 | |
Sandra K Walker, ARNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 325 9th Ave, Seattle, WA 98104 Phone: 206-598-0502 Fax: 206-598-0516 | |
Ms. Jennifer Patano, CNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 4800 Sand Point Way Ne, Ms O.7.720, Seattle, WA 98105 Phone: 206-987-8949 Fax: 206-987-8943 | |
Mrs. Susan L Holtzclaw, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 4800 Sand Point Way Ne, Mailstop T-2108, Seattle, WA 98105 Phone: 206-987-5691 | |
Dr. Kaitlin Michelle Brasier, D.N.P., A.R.N.P., RN Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1525 4th Ave, Suite 300, Seattle, WA 98101 Phone: 206-838-6856 Fax: 206-838-3085 | |
Melissa Yen-ching Lo, DNP, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 825 Eastlake Ave E, Seattle, WA 98109 Phone: 206-861-3396 |